3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
33
Cisplatin
22
Carboplatin
16
Magnetic Resonance Spectroscopy
15
Specimen Handling
12
Cetuximab
12
Radiotherapy, Intensity-Modulated
11
Paclitaxel
9
Platinum
8
Nivolumab
8
1,2-diaminocyclohexaneplatinum II citrate
8
atezolizumab
5
Taxes
5
Radiotherapy
5
Docetaxel
5
Biopsy
5
Fluorouracil
4
(225)Ac-DOTA-c(RGDyK)
4
dostarlimab
3
cemiplimab
3
Radiotherapy, Image-Guided
3
Radiation
3
Fulvestrant
3
Bevacizumab
3
tislelizumab
2
dehydroftorafur
2
budigalimab
2
amivantamab
2
abemaciclib
2
Tiragolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.